Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15054133 | 1.00 | ALDH1A1 (0.41) | ALDH1A1KMT2AKDM4EMEN1L3MBTL1 | |
| SCHEMBL2218547 | 0.83 | NPSR1 (0.47) | ALDH1A1KMT2AKDM4EL3MBTL1MAPT | |
| SCHEMBL19439493 | 0.76 | ALDH1A1 (0.44) | ALDH1A1KMT2AKDM4EMEN1L3MBTL1 | |
| SCHEMBL18076658 | 0.75 | KMT2A (0.44) | ALDH1A1KMT2AKDM4EMEN1L3MBTL1 | |
| SCHEMBL27653001 | 0.74 | CTSD (0.43) | ALDH1A1KMT2AKDM4EMEN1L3MBTL1 | |
| SCHEMBL460830 | 0.73 | ALDH1A1 (0.40) | ALDH1A1KMT2AMEN1L3MBTL1POLB | |
| SCHEMBL8859336 | 0.71 | KMT2A (0.46) | ALDH1A1KMT2AKDM4EMEN1MAPT | |
| SCHEMBL7064399 | 0.71 | PTPN1 (0.48) | ALDH1A1KMT2AKDM4EMEN1MAPT | |
| Hydrogen Peroxide SCHEMBL28789392 | 0.71 | GPR35 (0.64) | ALDH1A1KMT2AMEN1L3MBTL1MAPT | |
| SCHEMBL4438391 | 0.70 | KMT2A (0.36) | ALDH1A1KMT2AKDM4EL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150148311-A1 | NON-SYSTEMIC TGR5 AGONISTS | ARDELYX INC (US) | 2015-05-28 | — | — | US | disclosed |
| EP-2794576-A1 | NON-SYSTEMIC TGR5 AGONISTS | Ardelyx, Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013096771-A1 | NON-SYSTEMIC TGR5 AGONISTS | ARDELYX, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148311-A1 | NON-SYSTEMIC TGR5 AGONISTS | GLP1R, GPR119, TRHR | ALDH1A1 3587/4885KMT2A 1662/4885KDM4E 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.